Granules India Limited (NSE:GRANULES)
India
· Delayed Price · Currency is INR | Market Cap | 116.22B |
| Revenue (ttm) | 44.60B |
| Net Income (ttm) | 4.79B |
| Shares Out | n/a |
| EPS (ttm) | 19.75 |
| PE Ratio | 24.26 |
| Forward PE | n/a |
| Dividend | 1.50 (0.31%) |
| Ex-Dividend Date | n/a |
| Volume | 625,077 |
| Average Volume | 1,534,343 |
| Open | 480.05 |
| Previous Close | 478.70 |
| Day's Range | 468.50 - 483.00 |
| 52-Week Range | 389.35 - 721.00 |
| Beta | 0.31 |
| RSI | 36.96 |
| Earnings Date | May 16, 2025 |
About Granules India
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, Africa, the Middle East, and internationally. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers various FDs, such as tablets, caplets, and press-fit capsules in bulk, blister p... [Read more]
Financial Performance
In 2023, Granules India's revenue was 45.06 billion, a decrease of -0.12% compared to the previous year's 45.12 billion. Earnings were 4.05 billion, a decrease of -21.54%.
Financial StatementsNews
Granules India shares drop nearly 3% amid US FDA warning letter
Granules India Limited saw its stock price decline by 2.75% to ₹458.65 on the NSE after the U.S. Food and Drug Administration (FDA) issued a warning letter related to its Gagillapur unit. Key Details ...
Granules India shares drop 3.6% after receiving US FDA warning letter for Gagillapur facility
Shares of Granules India declined over 3% after the company received a Warning Letter from the US Food and Drug Administration (FDA) regarding its Gagillapur facility. The letter follows an inspection...
Top Stocks in News Today, Friday, February 28: GE Power, Coal India, Sanofi, Granules India, RVNL, Transrail Lighting, TATA Motors and more
Indian equity indices ended on a flat note with the Nifty closing at 22,550 on February 27. The Sensex closed marginally higher, up 10.31 points or 0.01 percent at 74,612.43, while the Nifty was down ...
USFDA issues warning letter to Granules’ Gagillapur unit, new product nods to take hit
Hyderabad: In a major setback for Hyderabad-based pharma player Granules India Ltd, the US Food and Drug Administration (USFDA) issued a warning lette.
Granules India receives US FDA warning letter for Gagillapur facility
Granules India Ltd has received a Warning Letter from the US Food and Drug Administration (FDA) regarding its Gagillapur facility. The letter follows an inspection conducted in August 2024, which resu...
Granules India acquires Senn Chemicals to expand into peptide segment and CDMO business
Granules India Limited has announced the signing of an agreement to acquire Senn Chemicals AG, a Swiss-based Contract Development and Manufacturing Organization (CDMO) specializing in peptides. The ac...
Granules India gains FDA approval for generic Vyvanse capsules
Granules India Limited, through its wholly-owned foreign subsidiary Granules Pharmaceuticals, Inc. (GPI), secured final approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated Ne...
Granules India shares fall nearly 4% on Q3 results
Granules India Limited released its unaudited consolidated financial results for the quarter ended December 31, 2024, revealing a decline in both revenue and net profit on a year-over-year basis, caus...
Granules India large trade: 1.3% equity worth Rs 191 crore changes hands
Granules India witnessed a significant block deal today as 32 lakh shares, representing 1.3% of the company’s equity, were traded for ₹191 crore. The shares exchanged hands at a price of ₹596 per shar...
Granules India receives USFDA approval for Lisdexamfetamine Dimesylate Chewable tablets
Granules India Limited, a leading Indian pharmaceutical company, has announced that its wholly-owned subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received approval from the U.S. Food & Drug A...
Compliance issues at Granules India’s Gagillapur plant
Granules India Ltd's Gagillapur plant in Hyderabad receives an official action indicated (OAI) classification from the US FDA after significant compliance issues including microbial contamination and ...
Granules India says US FDA action may impact new product approvals, expect meet with FDA soon
Granules India provides an update regarding the US FDA’s classification of its Gagillapur facility under “Official Action Initiated” (OAI), as per the recent communication on December 3, 2024. This cl...
Granules India stock falls over 10% from day’s high as US FDA classifies inspection as “Official Action Indicated”
Shares of Granules India witnessed a decline of on Monday, trading at ₹563 after opening at ₹614.30. The stock’s downward movement comes in response to the latest announcement concerning the company’s...
Granules India’s Gagillapur facility receives OAI classification from US FDA
Granules India Ltd has provided a significant update regarding the recent US FDA inspection of its Gagillapur facility in Hyderabad, Telangana. As per the company’s communication on September 7, 2024,...
Granules India achieves SBTi approval for ambitious net-zero goals
Granules India Limited has received SBTi approval for their climate commitments, targeting a 42% reduction in emissions by 2030 and striving for net-zero GHG emissions across their operations by FY205...
Granules India’s Unit V facility in Andhra Pradesh gets US FDA EIR with NAI status
India Business News: HYDERABAD: Pharma player Granules India Limited on Friday said it has received an Establishment Inspection Report (EIR) from the US Food and Drug Admi.
Granules India shares surge 2% after US FDA grants ‘No Action Indicated’ status to Andhra Pradesh facility
Granules India shares surged more than 2% after the US FDA granted its Andhra Pradesh Unit V facility a ‘No Action Indicated’ (NAI) status. This designation follows a recent inspection, confirming tha...
Granules India’s Andhra Pradesh facility receives ‘No Action Indicated’ status from US FDA
Granules India Limited, a prominent pharmaceutical manufacturer, has achieved a significant milestone as it received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration...
Granules India Q2 FY25 Results: Revenue drops 19%, Net Profit declines 5% YoY
Granules India Limited, a prominent player in the pharmaceutical industry, has announced its financial results for the second quarter of FY25, reporting a mixed performance marked by a decline in both...
Granules India Q2 FY25 results: Stock jumps 2% ahead of result announcement
Granules India Limited saw its shares jumped 2% in the morning trade session, signalling strong investor interest ahead of the company’s much-anticipated Q2 FY25 earnings results. The shares opened at...
Stocks to Buy This Diwali: Granules India – Share India recommends with a target of ₹770, potential upside 26%
Granules India Ltd, a key player in the pharmaceutical industry, has been recommended by Share India with a buy range of ₹590-610 and a target price of ₹770, offering a potential upside of 26%. The co...
Granules India gets USFDA approval for Bupropion Hydrochloride Extended-Release tablets
Granules India has recently informed exchanges that the company received USFDA approval for Bupropion Hydrochloride Extended-Release Tablets, a medication for depression and seasonal affective disorde...
F&O Ban List for October 4: Granules India, Manappuram Finance, Bandhan Bank and more
As of October 4, 2024, the following stocks have entered the F&O ban period: When the open interest (OI) on a stock surpasses 95% of the market-wide position limits (MWPL), the stock’s futures and opt...
Pharma Stocks Update: Granules up 3.56%, Ajanta Pharma gains 2.24% while JB Chemicals drops 2.82%, Mankind Pharma down 1.40% in mixed pharma stock performance
Pharma stocks have shown mixed performance in today’s trading session, with some major players gaining ground while others face declines. As of now, here’s how key pharmaceutical stocks are performing...
F&O ban: ABFRL, Granules, Hindustan Copper, IEX, and Vodafone Idea exit ban [Sept 27, 2024]
In today’s futures and options (F&O) segment, there are no stocks under the ban list. Meanwhile, the following stocks have exited the F&O ban: Aditya Birla Fashion and Retail (ABFRL) Granules India (G...